Literature DB >> 10452838

Growth of MDA-MB-231 cell line: different effects of TGF-beta(1), EGF and estradiol depending on the length of exposure.

C Mur1, P A Martínez-Carpio, M E Fernández-Montolí, J M Ramon, P Rosel, M A Navarro.   

Abstract

The human cell line MDA-MB-231 is a prototype for the study of hormone-independent breast cancer. Modification of cell growth behaviour has been observed after treating these cells with growth factors. EGF is a typical stimulatory growth factor for many cell types, whereas transforming growth factor beta(1)(TGF-beta(1)) acts with inhibitory character. Here we observed cell growth inhibition after EGF as well as after TGF-beta(1)treatments. Nevertheless, in the 42-h experiments, EGF-treated cultures grew before (18 hours) respect to the TGF-beta(1)and E(2)-treated cultures (24 h), and in the 11-day experiments, EGF-treated cultures started growing (7 days) after TGF-beta(1)-treated cultures (5 days). Estradiol inhibited the proliferation of these cells only after several days of treatment. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10452838     DOI: 10.1006/cbir.1998.0306

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  3 in total

1.  Apoptotic Effect of Wortmannolone on Cancer Cells through Potent ROS Induction.

Authors:  Ulyana Muñoz Acuña; Nighat Fatima; Safia Ahmed; Leng Chee Chang; Esperanza J Carcache de Blanco
Journal:  Int J Cancer Res (Tortola)       Date:  2013-11

Review 2.  Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Authors:  Dingcheng Gao; Linda T Vahdat; Stephen Wong; Jenny C Chang; Vivek Mittal
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

3.  Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells.

Authors:  Ulyana Muñoz Acuña; Jennifer Wittwer; Sloan Ayers; Cedric J Pearce; Nicholas H Oberlies; Esperanza J Carcache DE Blanco
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.